Transaxillary subpectoral augmentation mammaplasty: a single surgeon's 20-year experience.
Abstract
[BACKGROUND] Transaxillary subpectoral augmentation mammaplasty (TASPA) is not widely accepted due to perceived limitations in pocket access, visualization, control, and subsequent risk for postoperative complications. Current published data do little to substantiate or refute those claims.
[OBJECTIVE] A retrospective chart review of a single surgeon's 20-year experience with the TASPA technique was undertaken to assess the incidence of total secondary procedures, implant-related revisions, and reoperations unrelated to the implant.
[METHODS] The senior author (DCM) performed 1776 primary TASPA procedures from January 1989 through December 2008. Of those, 94 patients did not meet inclusion criteria, leaving a total of 1682 records for analysis. Data reviewed included age, date of surgery, race, implant size and type, manufacturer, and reasons for reoperation.
[RESULTS] Average age was 32.7 ± 8.1 years (range, 16-62). Average implant size was 438.5 ± 51.5 cc (range, 270-630). Implants from Allergan/Inamed/McGhan (Irvine, CA), Dow-Corning (Midland, MI), Mentor (Santa Barbara, CA), and Surgitek (Racine, PA) were inserted (n = 2094 saline, n = 1270 silicone). Mean follow-up time was 37.9 ± 45.4 months (range, one month to 19.8 years). Excluding staged mastopexies and treatment for breast cancer, total secondary procedures were required in 225 patients (13.4%). Implant-related revisions included malposition (2.97%), size change (2.5%), and capsular contracture (1.9%). Perioperatively, no infections occurred, and two patients (0.12%) experienced hematoma. Most reoperations (62.8%) were performed through the axilla. Comparison to published data showed an equal or lower rate of capsular contracture, hematoma, and infection with the TASPA approach.
[CONCLUSIONS] Given its advantages of an inconspicuous scar, decreased infection, and decreased capsular contracture, TASPA can be safely offered to patients as an option in breast augmentation.
[OBJECTIVE] A retrospective chart review of a single surgeon's 20-year experience with the TASPA technique was undertaken to assess the incidence of total secondary procedures, implant-related revisions, and reoperations unrelated to the implant.
[METHODS] The senior author (DCM) performed 1776 primary TASPA procedures from January 1989 through December 2008. Of those, 94 patients did not meet inclusion criteria, leaving a total of 1682 records for analysis. Data reviewed included age, date of surgery, race, implant size and type, manufacturer, and reasons for reoperation.
[RESULTS] Average age was 32.7 ± 8.1 years (range, 16-62). Average implant size was 438.5 ± 51.5 cc (range, 270-630). Implants from Allergan/Inamed/McGhan (Irvine, CA), Dow-Corning (Midland, MI), Mentor (Santa Barbara, CA), and Surgitek (Racine, PA) were inserted (n = 2094 saline, n = 1270 silicone). Mean follow-up time was 37.9 ± 45.4 months (range, one month to 19.8 years). Excluding staged mastopexies and treatment for breast cancer, total secondary procedures were required in 225 patients (13.4%). Implant-related revisions included malposition (2.97%), size change (2.5%), and capsular contracture (1.9%). Perioperatively, no infections occurred, and two patients (0.12%) experienced hematoma. Most reoperations (62.8%) were performed through the axilla. Comparison to published data showed an equal or lower rate of capsular contracture, hematoma, and infection with the TASPA approach.
[CONCLUSIONS] Given its advantages of an inconspicuous scar, decreased infection, and decreased capsular contracture, TASPA can be safely offered to patients as an option in breast augmentation.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 합병증 | capsular contracture
|
피막구축 | dict | 3 | |
| 시술 | mammaplasty
|
유방성형술 | dict | 2 | |
| 해부 | breast
|
유방 | dict | 2 | |
| 합병증 | hematoma
|
혈종 | dict | 2 | |
| 합병증 | infection
|
감염 | dict | 2 | |
| 기법 | subpectoral
|
근막하 평면 | dict | 2 | |
| 시술 | breast augmentation
|
유방성형술 | dict | 1 | |
| 합병증 | implant-related
|
scispacy | 1 | ||
| 합병증 | axilla
|
scispacy | 1 | ||
| 합병증 | scar
|
scispacy | 1 | ||
| 약물 | DCM
|
C0007193
Cardiomyopathy, Dilated
|
scispacy | 1 | |
| 약물 | Allergan/Inamed/McGhan
|
scispacy | 1 | ||
| 약물 | silicone
|
C0037114
silicones
|
scispacy | 1 | |
| 약물 | ± 45.4 months
|
scispacy | 1 | ||
| 약물 | [BACKGROUND] Transaxillary subpectoral augmentation
|
scispacy | 1 | ||
| 약물 | [OBJECTIVE] A
|
scispacy | 1 | ||
| 약물 | saline
|
scispacy | 1 | ||
| 약물 | [CONCLUSIONS]
|
scispacy | 1 | ||
| 질환 | breast cancer
|
C0006142
Malignant neoplasm of breast
|
scispacy | 1 | |
| 질환 | Implant-related
|
scispacy | 1 | ||
| 질환 | infections
|
C0851162
Infections of musculoskeletal system
|
scispacy | 1 | |
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | capsular
|
scispacy | 1 |
MeSH Terms
Adolescent; Adult; Axilla; Breast Implantation; Breast Implants; Female; Follow-Up Studies; Hematoma; Humans; Implant Capsular Contracture; Middle Aged; Reoperation; Retrospective Studies; Silicone Gels; Sodium Chloride; Treatment Outcome; Young Adult
📑 인용 관계
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- The impact of three-dimensional simulation and virtual reality technologies on surgical decision-making and postoperative satisfaction in aesthetic surgery: a preliminary study.
- Cutaneous fistula of the breast: A complication of cosmetic autologous fat transfer.
- Epidermal inclusion cyst after breast reduction mammoplasty.
- Penetrating globe injury following periocular hyaluronic acid filler injection: A case report.
- Clinical outcomes of synthetic absorbable mesh use in breast surgery: First case series in reconstruction and aesthetic mastopexy.